Etrasimod - Arena Pharmaceuticals

Drug Profile

Etrasimod - Arena Pharmaceuticals

Alternative Names: APD 334

Latest Information Update: 08 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Arena Pharmaceuticals
  • Class Antirheumatics; Immunotherapies; Indoles; Small molecules
  • Mechanism of Action Sphingosine 1 phosphate receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Inflammatory bowel diseases; Primary biliary cirrhosis; Pyoderma; Ulcerative colitis
  • Phase I Atopic dermatitis

Most Recent Events

  • 31 Oct 2018 Phase-I clinical trials in Atopic dermatitis (PO) (Arena Pharmaceuticals pipeline, November 2018)
  • 18 Oct 2018 Arena Pharmaceuticals terminates the phase II trial in Pyoderma in Australia and New Zealand (NCT03072953)
  • 16 Oct 2018 Arena Pharmaceuticals completes the phase III OASIS trial in Ulcerative colitis in Australia, Austria, Belgium, Bulgaria, the Czech Republic, France, Germany, Hungary, Israel, Latvia, Lithuania, New Zealand, Poland, Spain, Ukraine, United Kingdom, USA and Canada (NCT02447302)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top